and we are particularly excited to announce the updated SLS009 Phase 2a data at ASH in December and to provide topline data from cohorts four and five in patients with relapsed/refractory (R/R) acute ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...

Dr. Catalina Amador is a co-author. Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Dr. Justin M. Watts is a ...

Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...

Here, again, updated results, including data from the 600-milligram cohorts will be presented at ASH. We look forward to ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that ...